Bausch Health Companies (BHC) to Release Earnings on Thursday

Bausch Health Companies (NYSE:BHC) will release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Bausch Health Companies to post earnings of $0.74 per share for the quarter. Bausch Health Companies has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.01 by $0.14. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The company had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the company earned $1.02 EPS. Bausch Health Companies’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Companies Stock Performance

Shares of BHC stock traded up $0.05 during mid-day trading on Tuesday, reaching $8.93. 147,789 shares of the company’s stock traded hands, compared to its average volume of 2,750,077. The firm has a market capitalization of $3.26 billion, a PE ratio of -5.49 and a beta of 0.85. The firm has a 50 day moving average price of $9.31 and a two-hundred day moving average price of $8.19. Bausch Health Companies has a 12 month low of $5.57 and a 12 month high of $11.46.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Piper Sandler upped their target price on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Monday. Jefferies Financial Group cut their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Royal Bank of Canada dropped their target price on shares of Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a report on Tuesday, April 23rd. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $11.33.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.